Literature DB >> 3492985

Sepsis score and acute-phase protein response as predictors of outcome in septic surgical patients.

L Dominioni, R Dionigi, M Zanello, R Monico, R Cremaschi, R Dionigi, A Ballabio, M Massa, M Comelli, P Dal Ri.   

Abstract

In a series of 135 patients with severe surgical infections, we determined the sepsis score and the plasma level of the acute-phase proteins alpha-1-acid glycoprotein, alpha 1-antitrypsin, complement factor B, and C3. The initial sepsis score was a strong determinant of survival: in survivors it was significantly lower than in nonsurvivors. Only 8% of patients with a sepsis score above 20 survived. At the onset of severe sepsis, the plasma levels of all four acute-phase proteins were significantly lower in nonsurvivors. A significant elevation of C3a levels in the plasma of both surviving and nonsurviving patients indicated marked consumption of complement components in all patients with severe sepsis. A linear equation was developed to predict survival: sepsis index of survival (SIS) % = 121 + 0.26 (complement factor B) + 0.36 (alpha-1-acid glycoprotein)-6 (sepsis score). Based on our analysis, at the onset of severe sepsis, an SIS of 50% or more can correctly predict 88% of survivors and an SIS less than 50% can correctly predict 86% of nonsurvivors several days in advance of clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492985     DOI: 10.1001/archsurg.1987.01400140023001

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  11 in total

1.  Acute phase proteins and infectious complications after surgery for esophageal cancer.

Authors:  T Saito; A Kuwahara; K Shimoda; T Kinoshita; K Sato; M Miyahara; M Kobayashi
Journal:  Jpn J Surg       Date:  1991-11

2.  Factors influencing the acute phase protein levels in patients with esophageal cancer.

Authors:  T Saito; A Kuwahara; K Shimoda; T Kinoshita; K Sato; M Miyahara; M Kobayashi
Journal:  Jpn J Surg       Date:  1991-07

3.  A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection.

Authors:  K Yoshioka; D J Youngs; M R Keighley
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

4.  Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shock.

Authors:  G Pilz; K Werdan
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

Review 5.  Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe.

Authors:  P O Nyström; R Bax; E P Dellinger; L Dominioni; W A Knaus; J L Meakins; C Ohmann; J S Solomkin; H Wacha; D H Wittmann
Journal:  World J Surg       Date:  1990 Mar-Apr       Impact factor: 3.352

6.  [Follow-up of infected patients in an intensive care unit using the "infection score," endotoxin and AT III determination].

Authors:  R Grundmann; M Hornung
Journal:  Langenbecks Arch Chir       Date:  1988

7.  Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes.

Authors:  S P Campos; H Baumann
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

8.  Intraabdominal infections: classification, mortality, scoring and pathophysiology.

Authors:  R G Holzheimer; K H Muhrer; N L'Allemand; T Schmidt; K Henneking
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

9.  Effect of perioperative allogeneic red blood cell transfusion on the immune-inflammatory response after colorectal cancer resection.

Authors:  Lenuce Ribeiro Aziz Ydy; Natasha Slhessarenko; José Eduardo de Aguilar-Nascimento
Journal:  World J Surg       Date:  2007-10       Impact factor: 3.282

10.  Prospectively validated predictions of shock and organ failure in individual septic surgical patients: the Systemic Mediator Associated Response Test.

Authors:  G J Slotman
Journal:  Crit Care       Date:  2000-09-08       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.